Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Sabine Semrau

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7049-6003; OpenAlex author ID A5010448955. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 6

  1. Reply to: "Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology," "Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,… First author DOI 10.1200/jco-25-02926↗
  2. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  3. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  4. Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival. Co-author DOI 10.3389/fimmu.2024.1253072↗
  5. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  6. [FOLFIRINOX after resection of pancreatic cancer sets new standards-systemic therapy providing an impulse for local treatment in resectable pancreatic cancer]. Co-author DOI 10.1007/s00066-019-01449-2↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rainer Fietkau · 4 shared papers, 2021–2026 · strength 0.89
  2. Helmut Oettle · 4 shared papers, 2021–2026 · strength 0.89
  3. Dorota Łubgan · 4 shared papers, 2019–2026 · strength 0.71
  4. Robert Grützmann · 4 shared papers, 2021–2026 · strength 0.65
  5. Michael B. Ghadimi · 3 shared papers, 2021–2026 · strength 0.50
  6. Waldemar H. Uhl · 3 shared papers, 2021–2026 · strength 0.50
  7. Henriette Golcher · 3 shared papers, 2021–2026 · strength 0.50
  8. Anke Reinacher‐Schick · 3 shared papers, 2021–2026 · strength 0.50
  9. Uwe A. Wittel · 3 shared papers, 2021–2026 · strength 0.50
  10. Stefan Hubert Boeck · 3 shared papers, 2021–2026 · strength 0.50
  11. Andrea Tannapfel · 2 shared papers, 2025–2026 · strength 0.40
  12. Markus Hecht · 2 shared papers, 2025–2026 · strength 0.40
  13. Dirk Waldschmidt · 2 shared papers, 2025–2026 · strength 0.40
  14. Timur Buniatov · 1 shared paper, 2024 · strength 0.15
  15. Christian Krautz · 1 shared paper, 2024 · strength 0.15
  16. Yurdagül Zopf · 1 shared paper, 2024 · strength 0.15
  17. Axel Denz · 1 shared paper, 2024 · strength 0.15
  18. Frederik J. Hansen · 1 shared paper, 2024 · strength 0.15
  19. Danilo Hackner · 1 shared paper, 2024 · strength 0.15
  20. Anne Jacobsen · 1 shared paper, 2024 · strength 0.15
  21. Anke Mittelstädt · 1 shared paper, 2024 · strength 0.15
  22. Georg F. Weber · 1 shared paper, 2024 · strength 0.15
  23. Paul David · 1 shared paper, 2024 · strength 0.15
  24. Maximilian Brunner · 1 shared paper, 2024 · strength 0.15
  25. Werner Hohenberger · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.